Management of Hyperglycemia in the ICU

Target Glucose Levels

• The American Diabetes Association recommends initiating insulin therapy when blood glucose levels exceed 180 mg/dL (10 mmol/L) in critically ill patients 1, 2, 3
• The American College of Endocrinology suggests maintaining glucose values between 140-180 mg/dL (7.8-10.0 mmol/L) for most ICU patients 4, 5, 6
• More stringent targets (110-140 mg/dL or 6.1-7.8 mmol/L) may be appropriate only for select patients, such as cardiac surgery patients or those with acute ischemic cardiac/neurological events, but only when these targets can be achieved without significant hypoglycemia 2, 4
• The Endocrine Society recommends avoiding glucose targets below 110 mg/dL (6.1 mmol/L) due to increased risk of hypoglycemia without additional clinical benefit 4, 6

Insulin Administration Method

• The American Association of Clinical Endocrinologists prefers continuous intravenous insulin infusion (CII) as the method for glycemic control in the ICU 1, 2, 3
• IV insulin's short half-life (<15 min) allows for rapid dose adjustments in response to changes in clinical status or nutrition 2, 7
• CII typically achieves target glucose levels within 4-8 hours 1, 3
• The Society of Critical Care Medicine suggests avoiding subcutaneous insulin in critically ill patients, particularly during hypotension or shock 1, 2

Implementation Strategies

• Computer-based algorithms for insulin infusion management have shown benefits including lower rates of hypoglycemia and reduced glycemic variability 1

Monitoring and Safety Considerations

• The American Diabetes Association emphasizes the importance of frequent blood glucose monitoring to prevent hypoglycemia 4
• Hypoglycemia (blood glucose <70 mg/dL or 3.9 mmol/L) is a significant adverse event that must be avoided 5
• Severe hypoglycemia (<40 mg/dL or 2.2 mmol/L) is associated with cognitive impairment and increased mortality 5
• The Endocrine Society recommends careful monitoring of potassium levels, as hypokalaemia is common during treatment of hyperglycemic crises 4

Special Considerations

• For patients with ischemic events (myocardial infarction or stroke), rapid control of glucose values is warranted, but intensive lowering has not shown additional benefit 4
• Patients with hyperglycemic crises (diabetic ketoacidosis or hyperosmolar hyperglycemic state) should receive continuous insulin infusion according to specific protocols 4, 8
• When transitioning from IV to subcutaneous insulin, consider factors such as stable glucose measurements for at least 4-6 hours, resolution of acidosis in diabetic ketoacidosis, hemodynamic stability, and stable nutrition plan 4

Common Pitfalls to Avoid

• The American Association of Clinical Endocrinologists advises against using sliding scale insulin as the sole regimen, which results in undesirable glycemic fluctuations 1, 2
• Setting overly stringent glucose targets (<110 mg/dL) increases hypoglycemia risk without improving outcomes 4, 6
• Inadequate monitoring of glucose levels, particularly during insulin infusion, is a common pitfall 5

Treatment Threshold for Rapid-Acting Insulin in Elderly Frail ICU Patients

Primary Recommendation: The 180 mg/dL Threshold

• The American Diabetes Association, Society of Critical Care Medicine, and Society of Thoracic Surgeons recommend that a glucose level >180 mg/dL should trigger initiation of insulin therapy in ICU patients, with the goal of maintaining glucose values between 140-180 mg/dL while avoiding hypoglycemia 9, 10, 11
• This threshold applies specifically to elderly frail patients, as the guidelines emphasize following general adult ICU recommendations but with heightened emphasis on preventing hypoglycemia in this vulnerable population 10

Critical Distinction: IV Insulin vs. Subcutaneous Rapid-Acting Insulin

• In the ICU setting, continuous intravenous insulin infusion (not subcutaneous rapid-acting insulin) is the preferred method for managing hyperglycemia once the 180 mg/dL threshold is exceeded 9, 10, 11
• Subcutaneous insulin should be avoided in critically ill ICU patients, particularly during hypotension or shock, as it has not been formally studied in this population and absorption is unreliable 10, 11
• The short half-life of IV insulin (<15 minutes) allows for rapid dose adjustments in response to the unpredictable changes in nutrition and clinical status common in frail elderly ICU patients 9, 11

When Subcutaneous Rapid-Acting Insulin IS Appropriate

• Subcutaneous rapid-acting insulin analogs (aspart, glulisine, lispro) are only appropriate for elderly frail patients once they transition OUT of the ICU to non-critical care settings 10, 12, 13
• In non-ICU settings with reduced oral intake, start with a reduced total daily dose of 0.1-0.15 units/kg/day, given mainly as basal insulin 12, 13
• Administer additional rapid-acting insulin analogs as correctional coverage for glucose levels >180 mg/dL before meals and at bedtime 12, 13

Special Considerations for Elderly Frail Patients

• Elderly frail patients have significantly elevated hypoglycemia risk due to multiple factors, including renal failure, malnutrition, malignancies, dementia, and frailty itself 9
• Elderly patients fail to perceive neuroglycopenic and autonomic hypoglycemic symptoms, delaying recognition and treatment 9
• Reduced renal gluconeogenesis, decreased food intake, and impaired counterregulatory hormonal responses all contribute to hypoglycemia risk 9

Common Pitfalls to Avoid

• Do not pursue more stringent glucose targets (<110-140 mg/dL) in elderly frail ICU patients unless they are highly select cases where targets can be achieved without significant hypoglycemia 10
• Never use sliding scale insulin as the sole regimen, as it results in undesirable glycemic fluctuations and increased hospital complications 10, 11
• Avoid subcutaneous insulin of any type in the acute ICU phase for critically ill patients, as absorption is unreliable and dangerous during hemodynamic instability 10, 11

Blood Glucose Management in the Intensive Care Unit

Initiation Threshold and Target Range

• Initiate continuous intravenous insulin when blood glucose persistently exceeds 180 mg/dL on two consecutive measurements, and aim to keep glucose within 140–180 mg/dL for the majority of critically ill patients. This recommendation is supported by the American Diabetes Association, the Society of Critical Care Medicine, and the American College of Endocrinology. [Evidence: strong – consensus guideline] 14

• The 140–180 mg/dL target derives from the NICE‑SUGAR randomized trial, which showed that intensive glucose control (80–110 mg/dL) increased mortality (27.5 % vs 25 % in the moderate‑control group) and produced a 10–15‑fold rise in severe hypoglycemia. [Evidence: high – multicenter RCT] 14

• Hyperglycemia is defined as blood glucose >140 mg/dL; at this level clinicians should consider measures such as reducing dextrose infusions, but formal insulin therapy is only initiated once the 180 mg/dL threshold is reached. [Evidence: moderate – expert consensus] [15][14]

More Stringent Targets for Selected Patients

• A tighter glucose range of 110–140 mg/dL may be considered only for highly selected patients (e.g., cardiac surgery, acute ischemic cardiac or neurological events) provided the target can be achieved without a significant increase in hypoglycemia. [Evidence: moderate – subgroup analysis] 14

• The original Van den Berghe surgical‑ICU trial demonstrated a ≈40 % reduction in mortality with an 80–110 mg/dL target, but subsequent studies have failed to reproduce this benefit in broader ICU populations. [Evidence: moderate – single‑center RCT] 14

• For the general ICU population, the risk‑benefit balance strongly favors the 140–180 mg/dL range. [Evidence: moderate – meta‑analysis] [15][14]

Protocol Implementation

• Use validated written or computerized insulin‑infusion protocols that specify predefined dose adjustments based on real‑time glucose values. [Evidence: moderate – guideline recommendation] 14

• Protocols should define a primary safety endpoint of a low hypoglycemia rate (≤70 mg/dL). [Evidence: moderate – consensus] 15

Definition and Clinical Impact of Hypoglycemia

• Hypoglycemia severity is categorized as:
  
  • Level 1: 54–70 mg/dL
  • Level 2: <54 mg/dL
  • Level 3: Neuroglycopenic symptoms or altered mental status requiring assistance.
    [Evidence: moderate – guideline classification] 14

Quality‑Improvement and Accreditation

• The Joint Commission’s accreditation program for hospital diabetes care supplies resources that help standardize inpatient glucose‑management practices. [Evidence: low – organizational guideline] 14